USA flag logo/image

An Official Website of the United States Government

OTHER FUNCTIONS DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR ALK MUTATIONS.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44CO120047
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
INSIGHT GENETICS, INC.
2 International Plaza Drive Suite 510 NASHVILLE, TN 37217
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: OTHER FUNCTIONS DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR ALK MUTATIONS.
Agency: HHS
Contract: N44CO120047
Award Amount: $1,495,220.00
 

Abstract:

Constitutively activated forms of ALK caused by genetic aberrations have been shown to cause an expanding variety of human cancers. The FDA recently approved the Pfizer drug Xalkori (crizotinib) to treat patients with non-small cell lung cancers (NSCLC) that express ALK. Numerous other pharmaceutical companies (ARIAD, Novartis, Synta, Xcovery, others) have ongoing ALK small-molecule inhibitor programs. The current diagnostic standard an ALK break-apart FISH assay has low sensitivity and is difficult tointerpret, creating a precarious situation for clinicians attempting to select the proper patients for ALK inhibitor treatment. Insight Genetics has therefore designed a qPCR platform, Insight ALK Screen , to provide highly sensitive and unambiguous identification of the complete spectrum of oncogenic ALK. During Phase I development, Insight ALK Screen was shown to be agnostic with regard to the 5 fusion partner of ALK, highly sensitive in cell line dilution studies, and highly specific in FFPE NSCLC patient specimens. Phase II will demonstrate clinical utility of the assay by testing a large cohort of clinical specimens to unequivocally demonstrate statistical significance in sound patient selection for ALK inhibitor therapy. The product will then enter co-development with IVD partner, QIAGEN, for commercialization of the assay as a FDA-approved companion diagnostic.

Principal Investigator:

David Hout
615-255-8880
DHOUT@INSIGHTGENETICSINC.COM

Business Contact:

David Hout
615-255-8880
DHOUT@INSIGHTGENETICSINC.COM
Small Business Information at Submission:

INSIGHT GENETICS, INC.
2 International Plaza Drive Suite 510 NASHVILLE, TN 37217

EIN/Tax ID: 120212289
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No